| Citation: |
HUANG Pei-xin, ZHANG Lan, CHEN Yi. Management of hepatotoxicity related to immune checkpoint inhibitors treatment[J]. Chin J Clin Med, 2020, 27(6): 926-930. DOI: 10.12025/j.issn.1008-6358.2020.20200562
|
Immune checkpoint inhibitors (ICIs) have shown remarkable effect in the treatment of malignant tumor, which has opened a new era of tumor immunotherapy. However, with the wide application of ICIs, non-specific immune activation due to the drugs brought a series of immune-related adverse events (irAEs). Liver is a vital organ of drug metabolism and digestion. Therefore, immune-related hepatotoxicity should be concerned by clinicians. Early detection, early diagnosis, and standard treatment are the key points to improve the prognosis. Here, this review briefly described the incidence and possible mechanism of irAEs, and summarized the present management of immune-related hepatotoxicity.
| [1] |
EL-KHOUEIRY A B, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040):an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502. DOI: 10.1016/S0140-6736(17)31046-2
|
| [2] |
ZHU A X, FINN R S, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224):a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7):940-952. DOI: 10.1016/S1470-2045(18)30351-6
|
| [3] |
LIU X, QIN S. Immune checkpoint inhibitors in hepatocellular carcinoma:opportunities and challenges[J]. Oncologist, 2019, 24(Suppl 1):S3-S10. DOI: 10.1002/hep.30337
|
| [4] |
SANMAMED M F, CHEN L. A paradigm shift in cancer immunotherapy:from enhancement to normalization[J]. Cell, 2018, 175(2):313-326. DOI: 10.1016/j.cell.2018.09.035
|
| [5] |
CHEN D S, MELLMAN I. Oncology meets immunology:the cancer-immunity cycle[J]. Immunity, 2013, 39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012
|
| [6] |
POSTOW M A, SIDLOW R, HELLMANN M D. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2):158-168. DOI: 10.1056/NEJMra1703481
|
| [7] |
PUZANOV I, DIAB A, ABDALLAH K, et al. Managing toxicities associated with immune checkpoint inhibitors:consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017, 5(1):95. DOI: 10.1186/s40425-017-0300-z
|
| [8] |
CHOI J, LEE S Y. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors[J]. Immune Netw, 2020, 20(1):e9. DOI: 10.4110/in.2020.20.e9
|
| [9] |
HERRMANN J. Adverse cardiac effects of cancer therapies:cardiotoxicity and arrhythmia[J]. Nat Rev Cardiol, 2020, 17(8):474-502. DOI: 10.1038/s41569-020-0348-1
|
| [10] |
ZHENG K, QIU W, WANG H, et al. Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events[J]. Thorac Cancer, 2020, 11(6):1746-1751. DOI: 10.1111/1759-7714.13405
|
| [11] |
KUMAR V, CHAUDHARY N, GARG M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy[J]. Front Pharmacol, 2017, 8:49. DOI: 10.3389/fphar.2017.00049
|
| [12] |
BOUTROS C, TARHINI A, ROUTIER E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination[J]. Nat Rev Clin Oncol, 2016, 13(8):473-486. DOI: 10.1038/nrclinonc.2016.58
|
| [13] |
WANG D Y, SALEM J E, COHEN J V, et al. Fatal toxic effects associated with immune checkpoint inhibitors:a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12):1721-1728. DOI: 10.1001/jamaoncol.2018.3923
|
| [14] |
EGGERMONT A M, CHIARION-SILENI V, GROB J J, et al. Prolonged survival in stage Ⅲ melanoma with ipilimumab adjuvant therapy[J]. N Engl J Med, 2016, 375(19):1845-1855. DOI: 10.1056/NEJMoa1611299
|
| [15] |
UGUREL S, KIECKER F, FRÖHLING S, et al. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma[J]. Eur J Cancer, 2017, 83:142-145. DOI: 10.1016/j.ejca.2017.06.020
|
| [16] |
KHOJA L, DAY D, WEI-WU CHEN T, et al. Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors:a systematic review[J]. Ann Oncol, 2017, 28(10):2377-2385. DOI: 10.1093/annonc/mdx286
|
| [17] |
XU C, CHEN Y P, DU X J, et al. Comparative safety of immune checkpoint inhibitors in cancer:systematic review and network meta-analysis[J]. BMJ, 2018, 363:k4226.
|
| [18] |
LARKIN J, HODI F S, WOLCHOK J D. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med, 2015, 373(13):1270-1271. DOI: 10.1056/NEJMc1509660
|
| [19] |
NAIDOO J, PAGE D B, LI B T, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Ann Oncol, 2015, 26(12):2375-2391. DOI: 10.1093/annonc/mdv383
|
| [20] |
LARKIN J, CHIARION-SILENI V, GONZALEZ R, et al. Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL)(CheckMate 067)[J]. Eur J Cancer, 2015, 51:S664-S665.
|
| [21] |
JOHNCILLA M, MISDRAJI J, PRATT D S, et al. Ipilimumab-associated hepatitis:clinicopathologic characterization in a series of 11 cases[J]. Am J Surg Pathol, 2015, 39(8):1075-1084. DOI: 10.1097/PAS.0000000000000453
|
| [22] |
KIM K W, RAMAIYA N H, KRAJEWSKI K M, et al. Ipilimumab associated hepatitis:imaging and clinicopathologic findings[J]. Invest New Drugs, 2013, 31(4):1071-1077. DOI: 10.1007/s10637-013-9939-6
|
| [23] |
THOMPSON J A. New NCCN guidelines:recognition and management of immunotherapy-related toxicity[J]. J Natl Compr Canc Netw, 2018, 16(5S):594-596. DOI: 10.6004/jnccn.2018.0047
|
| [24] |
THOMPSON J A, SCHNEIDER B J, BRAHMER J, et al. Management of immunotherapy-related toxicities, version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(3):255-289. DOI: 10.6004/jnccn.2019.0013
|
| [25] |
HAANEN J B A G, CARBONNEL F, ROBERT C, et al. Management of toxicities from immunotherapy:ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4):iv264-iv266.
|
| [26] |
中国临床肿瘤学会.免疫检查点抑制剂相关的毒性管理指南[M].北京:人民卫生出版社, 2019.
|
| [27] |
MARTINS F, SYKIOTIS G P, MAILLARD M, et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities[J]. Lancet Oncol, 2019, 20(1):e54-e64. DOI: 10.1016/S1470-2045(18)30828-3
|
| [28] |
US Department of Health and Human Services, the National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events(CTCAE v5.0)[EB/OL].(2017-11-27)[2020-10-02]. https: //evs.nci.nih.gov//ftp1/CTCAE/CTCAE_5.0/.
|
| [29] |
SANGRO B, CHAN S L, MEYER T, et al. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2):320-341. DOI: 10.1016/j.jhep.2019.10.021
|
| [30] |
陆舜, 刘天舒.免疫检查点抑制剂相关不良事件的研究进展[J].中国临床医学, 2020, 27(6):903-908. http://www.c-jcm.com/zglcyx/ch/reader/view_abstract.aspx?file_no=20200601&flag=1
|
DownLoad: